Zhejiang Starry Pharm Co Ltd Total Assets
Zhejiang Starry Pharm Co Ltd total assets. Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) holds total assets worth CN¥6.27 Billion CNY (≈ $918.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Zhejiang Starry Pharm Co Ltd (603520) total market value for the company's overall valuation and market capitalisation.
Total Assets of Zhejiang Starry Pharm Co Ltd (2011–2025)
Total assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2025. This chart illustrates how Zhejiang Starry Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Zhejiang Starry Pharm Co Ltd for real-time trading data and today's change.
Zhejiang Starry Pharm Co Ltd - Asset Composition Analysis
Zhejiang Starry Pharm Co Ltd Total Assets Breakdown (December 2025)
Zhejiang Starry Pharm Co Ltd total assets breakdown as of December 2025. Zhejiang Starry Pharm Co Ltd's total assets of CN¥6.27 Billion consist of 36.9% current assets and 63.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.8% |
| Accounts Receivable | CN¥479.86 Million | 7.8% |
| Inventory | CN¥1.19 Billion | 19.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥291.24 Million | 4.7% |
| Goodwill | CN¥404.96 Million | 6.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Zhejiang Starry Pharm Co Ltd (603520) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhejiang Starry Pharm Co Ltd's current assets represent 36.9% of total assets in 2025, a decrease from 48.9% in 2011.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, up from 6.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 4.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 19.4% of total assets.
Zhejiang Starry Pharm Co Ltd Competitors by Total Assets
Key competitors of Zhejiang Starry Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Zhejiang Starry Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.83 | 1.27 |
| Quick Ratio | 0.53 | 0.44 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥53.61 Million | CN¥-461.57 Million | CN¥384.96 Million |
Zhejiang Starry Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhejiang Starry Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | CN¥6.16 Billion |
| Market Capitalization | $524.77 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhejiang Starry Pharm Co Ltd's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhejiang Starry Pharm Co Ltd's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhejiang Starry Pharm Co Ltd (2011–2025)
The table below shows the annual total assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.16 Billion ≈ $900.70 Million |
+1.81% |
| 2024-12-31 | CN¥6.05 Billion ≈ $884.66 Million |
+9.59% |
| 2023-12-31 | CN¥5.52 Billion ≈ $807.23 Million |
+4.04% |
| 2022-12-31 | CN¥5.30 Billion ≈ $775.88 Million |
+8.31% |
| 2021-12-31 | CN¥4.90 Billion ≈ $716.35 Million |
+11.10% |
| 2020-12-31 | CN¥4.41 Billion ≈ $644.79 Million |
+26.44% |
| 2019-12-31 | CN¥3.48 Billion ≈ $509.94 Million |
+13.63% |
| 2018-12-31 | CN¥3.07 Billion ≈ $448.77 Million |
+52.32% |
| 2017-12-31 | CN¥2.01 Billion ≈ $294.62 Million |
+6.33% |
| 2016-12-31 | CN¥1.89 Billion ≈ $277.08 Million |
+28.09% |
| 2015-12-31 | CN¥1.48 Billion ≈ $216.32 Million |
+28.50% |
| 2014-12-31 | CN¥1.15 Billion ≈ $168.35 Million |
+14.03% |
| 2013-12-31 | CN¥1.01 Billion ≈ $147.63 Million |
+22.23% |
| 2012-12-31 | CN¥825.38 Million ≈ $120.78 Million |
+13.99% |
| 2011-12-31 | CN¥724.08 Million ≈ $105.95 Million |
-- |
About Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more